These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 926103)
1. Colchicine in the treatment of scleroderma. Guttadauria M; Diamond H; Kaplan D J Rheumatol; 1977; 4(3):272-6. PubMed ID: 926103 [TBL] [Abstract][Full Text] [Related]
2. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Plastiras SC; Karadimitrakis SP; Ziakas PD; Vlachoyiannopoulos PG; Moutsopoulos HM; Tzelepis GE Arthritis Rheum; 2006 Aug; 55(4):598-602. PubMed ID: 16874782 [TBL] [Abstract][Full Text] [Related]
3. Long-term evaluation of colchicine in the treatment of scleroderma. Alarcon-Segovia D; Ramos-Niembro F; Ibanez de Kasep G; Alcocer J; Tamayo RP J Rheumatol; 1979; 6(6):705-12. PubMed ID: 529256 [TBL] [Abstract][Full Text] [Related]
4. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610 [TBL] [Abstract][Full Text] [Related]
5. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study. Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152 [TBL] [Abstract][Full Text] [Related]
6. Iloprost as cyclic five-day infusions in the treatment of scleroderma. An open pilot study in 20 patients treated for one year. Biasi D; Carletto A; Caramaschi P; Zeminian S; Pacor ML; Corrocher R; Bambara LM Rev Rhum Engl Ed; 1998 Dec; 65(12):745-50. PubMed ID: 9923042 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of oral methotrexate in the treatment of systemic sclerosis. Krishna Sumanth M; Sharma VK; Khaitan BK; Kapoor A; Tejasvi T Int J Dermatol; 2007 Feb; 46(2):218-23. PubMed ID: 17269983 [TBL] [Abstract][Full Text] [Related]
8. [Effect of colchicine in progressive systemic sclerosis]. Tanimoto K; Oohama Y; Yamada A; Moroi Y; Matsuo H Ryumachi; 1977 Jan; 17(1):56-62. PubMed ID: 847544 [No Abstract] [Full Text] [Related]
9. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease. Mittoo S; Wigley FM; Wise R; Xiao H; Hummers L Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251 [TBL] [Abstract][Full Text] [Related]
10. [Effect of a single dose of nifedipine on the CO transfer capacity in patients with scleroderma]. Orvoen-Frija E; Dore MF; Fiessinger JN; Rochemaure J Rev Mal Respir; 1989; 6(6):525-9. PubMed ID: 2602627 [TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. Silver RM; Warrick JH; Kinsella MB; Staudt LS; Baumann MH; Strange C J Rheumatol; 1993 May; 20(5):838-44. PubMed ID: 8336309 [TBL] [Abstract][Full Text] [Related]
12. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP; Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967 [TBL] [Abstract][Full Text] [Related]
13. Serial changes in scleroderma and idiopathic interstitial lung disease. Colp CR; Riker J; Williams MH Arch Intern Med; 1973 Oct; 132(4):506-15. PubMed ID: 4742404 [No Abstract] [Full Text] [Related]
14. [Longitudinal study of parameters of respiratory function tests and blood gas analysis in patients with progressive systemic scleroderma]. Georgiev O; Shoshkov P; Rashkov R Vutr Boles; 2001; 33(2-3):37-40. PubMed ID: 12001574 [TBL] [Abstract][Full Text] [Related]
15. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Lindor KD; Wiesner RH; Colwell LJ; Steiner B; Beaver S; LaRusso NF Am J Gastroenterol; 1991 Jan; 86(1):57-61. PubMed ID: 1986556 [TBL] [Abstract][Full Text] [Related]
16. [Value of certain colchicine derivatives in the treatment of sclerodermic syndromes]. Housset E Ann Dermatol Syphiligr (Paris); 1967; 94(1):31-4. PubMed ID: 6059735 [No Abstract] [Full Text] [Related]
17. Mechanisms of colchicine effect in the treatment of asbestosis and idiopathic pulmonary fibrosis. Addrizzo-Harris DJ; Harkin TJ; Tchou-Wong KM; McGuinness G; Goldring R; Cheng D; Rom DW Lung; 2002; 180(2):61-72. PubMed ID: 12172901 [TBL] [Abstract][Full Text] [Related]
18. [Studies of the respiratory function in scleroderma. Report on 5 cases]. Martínez Guerra L; Fernández Bonetti P; Balvanera Abreu A; Varela Carrillo M; Soní Cassani J Arch Inst Cardiol Mex; 1971; 41(5):525-30. PubMed ID: 5131720 [No Abstract] [Full Text] [Related]
19. [Madecassol treatment of systemic and localized scleroderma]. Guseva NG; Starovoĭtova MN; Mach ES Ter Arkh; 1998; 70(5):58-61. PubMed ID: 9644746 [TBL] [Abstract][Full Text] [Related]